Association between combined atherogenic and frailty index and cardiovascular events: evidence from the CHARLS cohort

动脉粥样硬化和衰弱指数与心血管事件的关联:来自CHARLS队列的证据

阅读:2

Abstract

OBJECTIVE: The atherogenic index of plasma (AIP) is a marker of atherosclerosis, while frailty reflects cumulative physiological decline. However, the combined impact of AIP-frailty index (AIP-FI) has not been adequately explored. This study aimed to investigate the association between AIP-FI and the risk of cardiovascular disease (CVD), stroke, and heart disease. METHODS: This prospective cohort study included 6896 participants aged ≥ 45 years from the China Health and Retirement Longitudinal Study (CHARLS) without CVD, stroke, or heart disease at baseline. The Cox proportional hazard models and restricted cubic spline (RCS) analysis were applied to explore the association between AIP-FI with the risk of CVD, stroke, and heart disease. RESULTS: During a median follow-up period of 9 years, 1648 (23.9%) of CVD events, 548 (7.9%) of stroke events, and 1280 (18.6%) of heart disease events were recorded. Cox regression analysis revealed that each 1-unit increment in the AIP-FI was significantly associated with higher risk of CVD (HR: 2.95, 95% CI 2.15, 4.05), stroke (HR: 3.14, 95% CI 1.88, 5.26), and heart disease (HR: 2.72, 95% CI 1.06, 1.89, 3.92). The RCS revealed a significant positive nonlinear relationship between AIP-FI with the risk of CVD, stroke, and heart disease (all P-overall < 0.05, and all P for non-linear < 0.05). CONCLUSIONS: Our study demonstrated that higher AIP-FI was significantly associated with increased risk of CVD, stroke, and heart disease. By integrating metabolic and frailty information, AIP-FI offers an effective and accessible tool for cardiovascular risk assessment, supporting earlier prevention and intervention strategies in the middle-aged and elderly Chinese populations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。